Genome-wide epigenomic screening can pinpoint disease-associated variants and identify novel genetic-epigenetic interactions in autoimmune thyroid diseases, according to new data presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada.
Since cytokines are key mediators of tissue inflammation and infiltration, a team of researchers from Mount Sinai School of Medicine in New York City tested the hypothesis that inflammatory cytokines, specifically interferon-alpha, a prime cytokine in the etiology of autoimmune thyroid disease, promote thyroid cell dysfunction through epigenetic modifications of autoimmune thyroid diseases genes. Interferon-alpha (IFNa) has also been shown to precipitate autoimmune thyroid diseases when used as therapeutic agent. The researchers had previously shown that IFNa increases mRNA expression of major AITD susceptibility genes in both cell lines and a mouse model of IFNa thyroid expression.
Researchers mapped modifications of histone patterns [histone H3 mono- and trimethylated at Lys-4 (H3K4me1 and H3K4me3)] induced by IFNa at these loci using ChIP-seq in human thyroid cells. ChIP-seq data were integrated with RNA-seq and bioinformatic analyses. Integration of ChIP-seq and RNA-seq data showed that significantly upregulated pathways included genes characterized by H3K4me3 enrichment in the 5'-regions, demonstrating a correlation between H3K4me3 and pathway activation by IFNa. Most upregulated genes/pathways participate in innate immunity and host defense response. IFNa induced enrichment of H3K4me1 mostly in noncoding gene regions.